Extracellular matrix and heparan sulfate proteoglycans (ECM/HSPGs)

The extracellular matrix (ECM) and heparan sulfate proteoglycans (HSPGs) form a dynamic scaffold that surrounds cells, providing both structural integrity and biochemical cues essential for tissue homeostasis. HSPGs are a specific class of glycoproteins, including syndecans, glypicans, and perlecan, which are modified with heparan sulfate glycosaminoglycan chains that bind to numerous proteins such as growth factors, cytokines, and extracellular matrix components (NIH, 2023). These molecules act as "co-receptors" that facilitate the assembly of signaling complexes on the cell surface, thereby regulating processes like cell proliferation, migration, and differentiation (PubMed, 2021). In pathological conditions like cancer, the ECM is often stiffened and HSPGs are degraded by enzymes like heparanase, which releases sequestered growth factors to drive angiogenesis and metastasis (Nature Reviews Cancer, 2020). Additionally, HSPGs serve as primary attachment sites for various viruses and bacteria, making them critical factors in infectious diseases (Journal of Virology, 2022). Therapeutic interventions targeting the ECM/HSPG axis include heparin mimetics and heparanase inhibitors designed to block pathological signaling and prevent tissue remodeling in cancer and inflammatory disorders (DrugBank, 2024).

Other names

ECMHSPGsPericellular matrixHeparan sulfate-bearing proteoglycansGlycosaminoglycan-rich extracellular matrix

Drugs targeting the ECM and HSPGs primarily function through heparanase inhibition, competitive displacement of growth factors (such as VEGF and FGF) from heparan sulfate chains, potentiation of antithrombin III to induce anticoagulation, and the blockade of viral or bacterial attachment to the cell surface.